PDCD1 and non-small cell lung carcinoma: Although a reliable biomarker predicting the effectiveness of neoadjuvant PD-1/PD-L1 blockades is yet to be found, a lot of interest has gained around the expression of PD-L1 (see Figure 1) following the studies showing responses to ICIs according to their expression in advanced NSCLC [14]